Pharmaceutical Technology

APRIL 4, 2023

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for AstraZeneca ’s Ultomiris (ravulizumab) to treat neuromyelitis optica spectrum disorder (NMOSD) in adult patients.

Marketing 130

Marketing Clinical Trials Clinical Trials Trials 130

Pharmaceutical Technology

JULY 7, 2022

But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. Often referred to as a type of gene-modified cell therapy, CAR-T cell therapies involve genetically modifying a patient’s own T cells to produce a protein that enables them to identify and kill cancer cells.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

BioTech 365

APRIL 21, 2021

Global Biochips Markets & Technologies Report 2021-2028: Microfluidics-based, Protein, Nanotechnology, Epigenetics, Drug Discovery & Development, Molecular Diagnostics & Personalized Medicine – ResearchAndMarkets.com Global Biochips Markets & Technologies Report 2021-2028: Microfluidics-based, Protein, Nanotechnology, Epigenetics, (..)

Protein 40

Protein Medicine Marketing Development 40

Pharmaceutical Technology

JANUARY 20, 2023

BeiGene has received marketing authorisations for Brukinsa (zanubrutinib) in Great Britain from the Medicines and Healthcare products Regulatory Agency (MHRA) to treat chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL).

Marketing 130

Marketing Bioavailability Trials Clinical Trials 130

Drug Discovery World

JULY 24, 2023

The EU’s Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorisation for 14 new medicines in its July meeting. Degarelix Accord (degarelix acetate), a generic medicine for the treatment of prostate cancer.

Medicine 52

Medicine Marketing Protein Vaccination 52

Pharmaceutical Technology

MAY 29, 2023

Novavax has received positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for full marketing authorisation (MA) of its Covid vaccine, Nuvaxovid (NVX-CoV2373) , in the European Union (EU). The safety and efficacy of Nuvaxovid was evaluated as a primary series.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

Drug Discovery World

FEBRUARY 20, 2024

The drug discovery informatics market is predicted to grow from $3.77 The new report says the anticipated growth to 2028 will be fuelled by the expansion of precision medicine, advancements in drug-drug interaction prediction, analysis of patient-derived data, development of biosimilars, and the increasing number of drug candidates.

Marketing 52

Marketing Drugs Life Science Genome 52

Roots Analysis

JANUARY 19, 2024

Introduction In a strategic move to accelerate the development and launch of genetic medicines, BridgeBio Pharma has successfully secured up to USD 1.25 ATTR is an inherited disease causing abnormal transthyretin protein and the accumulation of amyloid protein in various tissues, including the heart.

Genetics 40

Genetics Medicine Development Sales 40

Pharmaceutical Technology

JULY 6, 2022

The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

Pharma Mirror

OCTOBER 6, 2021

The rising need for early diagnosis of chronic diseases, coupled with growing demand for drugs which work better and have fewer side effects, is largely responsible for the growth of the protein A resin market. Chromatography requires an antibody to bind to a protein A resin.

Research 130

Research Protein Antibody Manufacturing 130

Pharmaceutical Technology

JULY 18, 2022

There are currently no approved therapies for the treatment of bronchiectasis; although some off-label medicines do exist, they only alleviate symptoms and manage frequent infections. CFTR modulators work by binding to the defective CFTR protein, improving its function, and in turn reducing the build-up of thick mucus.

Marketing 147

Marketing Trials Development Protein 147

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

Drug Discovery World

JUNE 1, 2023

A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2. DDW’s Megan Thomas explores three trends in the market. Varying sources suggest that China has been one to watch over recent years and continues to be going forward.

Antibody 98

Antibody Marketing Drugs Licensing 98

Pharmaceutical Technology

SEPTEMBER 14, 2022

The protein-based vaccine is indicated as a two-dose initial regimen for active immunisation for the prevention of Covid-19 in adults aged 18 years and above. It is marketed under the brand name Covovax in the country. As Covid-19 continues to evolve, having a choice of vaccines is critical to improving vaccination rates.”.

Vaccination 147

Vaccination Vaccine Clinical Trials Clinical Trials 147

Pharmaceutical Technology

JUNE 29, 2022

The next wave of medicine is well on course to be cell and gene-based. In September 2021, GlobalData figures revealed there to be 1,320 industry-sponsored regenerative medicine and advanced therapy trials ongoing worldwide. Meanwhile, the pharma industry is undergoing somewhat of a transformation itself.

Drugs 295

Drugs Gene Therapy Manufacturing Production 295

Delveinsight

SEPTEMBER 24, 2021

The diagnosis of the condition largely depends on the presence of the protein IgA as the dominant or co-dominant immunoglobulin in the glomerular mesangium by kidney biopsy with renal biopsy as the gold standard of the IgAN diagnosis. There is no availability of any disease-specific treatment for IgAN patients. million in 2020 in the 7MM. .

Pharma Companies 77

Pharma Companies Marketing Protein Drugs 77

Roots Analysis

JANUARY 28, 2024

Pharmaceutical Research: Big data analytics can be applied in various areas of pharmaceutical research, including drug discovery and development, precision medicine , clinical trial optimization, pharmacovigilance and drug safety, supply chain optimization, and real-time monitoring and surveillance.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Biopharmaceutical Excipient Manufacturing Market. Biopharmaceutical Excipient Manufacturing Market. Capacity Analysis.

Manufacturing 52

Manufacturing Marketing Contract Manufacturing Protein 52

Drug Discovery World

FEBRUARY 6, 2024

Companies leading the way There are a number of companies leading the charge in applying innovative technologies, particularly artificial intelligence (AI) and machine learning (ML), to the search for new medicines. Relation Therapeutics, which uses high-resolution biology, ML and clinical insights to discover transformational medicines.

Marketing 69

Marketing Medicine Genome Genomics 69

Pharmaceutical Technology

FEBRUARY 10, 2023

Access to oncology medicines varies across countries, and their cost against safety/efficacy is generally perceived as being low, such as in the US. However, more highly innovative/high-cost treatments, within infectious disease and neurology space, are likely to enter the market for rare disorders, increasing the number of non-oncology RSAs.

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

The Pharma Data

MARCH 30, 2021

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.

Protein 52

Protein Licensing Licensing Containment 52

Delveinsight

SEPTEMBER 6, 2021

The current explorations and evaluations in the Phenylketonuria therapy market comprise large neutral amino acid supplementation, which may help prevent phenylalanine from entering the brain, and enzyme replacement therapy, which uses a substance similar to the enzyme that usually breaks down phenylalanine.

Marketing 72

Marketing Gene Therapy Gene Clinical Trials 72

Pfizer

JANUARY 27, 2023

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Marketing 75

Marketing Production Drugs Licensing 75

pharmaphorum

APRIL 19, 2022

[So] we are trying to go for the international market.”. “In Kim says the Dry Eye Disease market is large and growing, with analysts predicting it will hit $6 billion USD by 2025. David Julius, who discovered TRPV1 in 1997, was recognized with Nobel Prize in Medicine last year for his work with TRP proteins). Conclusion.

Marketing 52

Marketing Clinical Trials Clinical Trials Licensing 52

Delveinsight

OCTOBER 1, 2021

This disease is associated with antibodies directed against the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic membrane at the neuromuscular junction. The current Myasthenia Gravis therapeutics market has many FDA-approved drugs for the treatment of Myasthenia Gravis.

Marketing 85

Marketing Antibody Drugs Sales 85

Drug Discovery World

OCTOBER 5, 2023

This free 2-hour Summit will take place online and will outline areas of advancement and opportunity in the cancer research market. Find out the answer to questions such as: Where is the opportunity in the cancer research market? More to be announced. What are the best research tools to aid development of new treatments and vaccines?

Research 52

Research Antibody Medicine RNA 52

Pharmaceutical Technology

MARCH 10, 2023

Personalised medicines will also be developed at the centre. The NHSBT hopes the CBC will increase the UK’s competitiveness within the market. Operations at the CBC will focus on building plasmids , viral vectors and recombinant proteins for the production of cell and gene therapies.

Gene Therapy 264

Gene Therapy Manufacturing Gene Clinical Trials 264

Drug Discovery World

SEPTEMBER 22, 2022

The European Medicines Agency said that the medicine “was shown to be effective at lowering the level of excess protein in the urine in patients with IgAN, indicating an improvement in kidney function”. Primary IgAN, also known as Berger’s disease, is a chronic, debilitating and life-threatening kidney disease.

Protein 52

Protein Medicine Drugs Marketing 52

Pharmaceutical Technology

JULY 18, 2022

The European Commission (EC) has granted conditional marketing authorization (CMA) for Calliditas Therapeutics’ Kinpeygo to treat primary immunoglobulin A (IgA) nephropathy (IgAN) in adults. The treatment is indicated for IgAN patients at risk of quick disease progression risk with a urine protein-to-creatinine ratio (UPCR) ?1.5g/gram.

Production 162

Production Clinical Trials Clinical Trials Protein 162

Drug Discovery World

OCTOBER 21, 2022

Bertis, a South Korean proteomics-based precision medicine technology company, has established a US-based wholly-owned entity to expand its global presence. The test received marketing approval as an in vitro diagnostic medical device from the Ministry of Food and Drug Safety in January 2019.

In-Vitro 52

In-Vitro Protein Medicine Research 52

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

The Pharma Data

JANUARY 24, 2021

–( BUSINESS WIRE )– Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., About Faze Medicines. 25, 2021 12:00 UTC. CAMBRIDGE, Mass.–( as its chief executive officer (CEO).

Medicine 52

Medicine Pharma Companies Gene Therapy Development 52

Pharmaceutical Technology

AUGUST 23, 2022

It comprises messenger ribonucleic acid (mRNA) that encodes for the initial spike protein of SARS-CoV-2 along with mRNA that encodes for Omicron BA.4/BA.5 5 variant spike protein. The companies have also commenced rolling submission for conditional marketing authorization from the European Medicines Agency (EMA) for this Omicron BA.4/BA.5-adapted

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

Pharmaceutical Technology

MAY 31, 2023

The therapeutic candidate targets immune checkpoint, programmed cell death protein 1 (PD1). Les Laboratoires Servier overview Les Laboratoires Servier (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. It is administered as an intravenous infusion.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

Pharmaceutical Technology

DECEMBER 23, 2022

It acts by hindering the protein shell (capsid) of the HIV-1 virus to hamper the viral lifecycle’s steps. Our goal is to deliver multiple long-acting options for treatment and prevention that are tailored to the needs of people living with HIV and people who could benefit from PrEP medicines.”.

Drugs 147

Drugs FDA Approval Clinical Trials Clinical Trials 147

The Pharma Data

SEPTEMBER 8, 2020

Fourteen newly licensed medicines have been accepted for use on NHS Scotland by the Scottish Medicines Consortium (SMC), bringing a raft of new treatment options for conditions including epilepsy, depression and cancer.

Medicine 52

Medicine Clinical Trials Clinical Trials Drugs 52

Pharmaceutical Technology

FEBRUARY 24, 2023

It is developed based on protein engineering platform. Merck overview Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It acts by targeting TGF-beta 1 and 3.

Production 100

Production Vaccination Vaccine Engineer 100